| Tofacitinib (n = 161) | Baricitinib (n = 81) | P value |
---|---|---|---|
All Events, n (%) | 32 (19.9) | 17 (21.0) | 0.866 |
Infection | 20 (12.4) | 11 (13.6) | 0.840 |
Herpes zoster | 9 (5.6) | 4 (4.9) | Â |
Pneumonia | 6 (3.7) | 1 (1.2) | Â |
Upper respiratory infection | 4 (2.5) | 3 (3.7) | Â |
Callus infection | Â | 1 (1.2) | Â |
Cytomegalovirus infection | Â | 1 (1.2) | Â |
Fungus infection | 1 (0.6) | Â | Â |
Sepsis | Â | 1 (1.2) | Â |
Gastrointestinal disorder | 6 (3.7) | 2 (2.5) | 0.720 |
Gastric ulcer | Â | 1 (1.2) | Â |
Nausea | 4 (2.5) | 1 (1.2) | Â |
Diarrhea | 2 (1.2) | Â | Â |
Neoplasm | 3 (1.9) | 1 (1.2) | > 0.999 |
Breast cancer | Â | 1 (1.2) | Â |
Colon cancer | 1 (0.6) | Â | Â |
Skin cancer | 1 (0.6) | Â | Â |
Lung cancer | 1 (0.6) | Â | Â |
Others | 3 (1.9) | 3 (3.7) | 0.405 |
Hair loss | 1 (0.6) | Â | Â |
Vertigo | 1 (0.6) | 1 (1.2) | Â |
Headache | Â | 1 (1.2) | Â |
Interstitial pneumonia | 1 (0.6) | Â | Â |
Elevation of creatine kinase | Â | 1 (1.2) | Â |